32 results about "P24 antigen" patented technology

The invention provides immunogenic compositions which enhance beta-chemokine levels in a mammal. The immunogenic compositions contain an HIV antigen, an isolated nucleic acid molecule containing an immunostimulatory sequence (ISS) and an adjuvant. The HIV antigen can be a whole-killed HIV virus devoid of outer envelope protein gp120. Alternatively, the HIV antigen can be a whole-killed HIV virus, or a p24 antigen. Also provided are kits, the components of which, when combined, produce the immunogenic compositions of the invention. The invention also provides methods of making the immunogenic compositions, by combining an HIV antigen, an isolated nucleic acid molecule containing an immunostimulatory sequence (ISS) and an adjuvant. The invention further provides a method of immunizing a mammal, by enhancing beta-chemokine production in the mammal by administering to the mammal an immunogenic composition containing an HIV antigen, an isolated nucleic acid molecule containing an immunostimulatory sequence (ISS) and an adjuvant. Also provided is a method of inhibiting AIDS, by enhancing beta-chemokine production in the mammal by administering to the mammal an immunogenic composition containing an HIV antigen, an isolated nucleic acid molecule containing an immunostimulatory sequence (ISS) and an adjuvant.

The invention relates to biology applied technology field, especially relates to a immune chromatography assay for quickly detecting the human immunologic deficiency disease (HIV) antibody and antigen. The assay comprises two independent test papers A and B and plastic case C for storing the test paper, wherein the test paper A is used for detecting the HIV antibody and the test paper B is used for detecting the HIV p24 antigen. The test paper A and test paper B are parallely encased in the plastic case to constitute the assay. On detecting, the detected sample is added on the sample pad of the test paler and the immunoreaction result is directly observed to perform detection. The assay is used for screening or clinical diagnosis of the HIV infection and at the same time the HIV antigen and antibody are detected, the simpler antibody detection can effectively reduce the window phase for detecting the HIV, with features of quick reaction, easy operation, economy and practicality, suitable for insitu detecting.

The invention discloses a fluorescence microballoon immunochromatography testing card for quantitatively testing HIV and preparation method. The testing card comprises A and B test paper, a sample cushion, a glass fibrous membrane, a nitrocellulose membrane and drinking paper, wherein, the nitrocellulose membrane is thereon fixed with a test line and a quality control line for realizing the simultaneous test of HIV antibody and HIV p24 antigen. The invention takes nucleocapsid dual-structural light-emitting nano-particles compounded by silicon dioxide and fluorescent substance as marks and adopts immunochromatographic technique to realize quantitative immunoassay of HIV. In the testing process, fluorescence microballoon excitation light source is adopted to carry out excitation, after the emitted fluorescence passes through an optical filter device, all emission spectra are collected, aggregated and multiplied by CCD scanning technique or optical fiber technique, and are then converted into numerical signals, the concentration of the substance to be measured is automatically calculated by using the built-in analysis software in a fluorescence analyzer. The invention has the advantages of high sensitivity, precise quota, fast detection, convenient operation, and economy and practicality.

The invention relates to a magnetic immunochromatographic test strip for combined detection of HIV-1+2 antibody and P24 antigen and a preparation method thereof. The test strip is assembled by pasting a coating film, magnetic particles combined with the HIV-1+2 antibody and the P24 antigen, a sample pad and a water-absorbing pad which are mutually staggered by 2 millimeters in turn on a bottom plate and then covering an upper layer with a transparent plastic sealing film, wherein the coated film is precoated with an HIV-1+2 antibody detection line, an HIV P24 antigen detection line and a quality control line. As the test strip introduces a magnetic immunochromatography technique and a biotin-avidin system into the combined detection of the HIV-1+2 antibody and the P24 antigen, the test strip has the advantages of greatly increasing detection sensitivity result accuracy, shortening detection window period and reducing the labor intensity of operators.

The invention relates to fluorescent nanoparticles Ru(bpy)3 / SiO2, a preparation method and application thereof. The fluorescent nanoparticles have nuclear shell structures; the nuclear shell structure is formed by taking tris(2,2'-bipyridyl)ruthenium as a core, covering silicon dioxide with netlike structure on the surface of the tris(2,2'-bipyridyl)ruthenium and carrying active amino groups on the surface of the silicon dioxide, wherein the mass ratio of the tris(2,2'-bipyridyl)ruthenium to the silicon dioxide is 1:5 to 1:8; and every milligram of nanoparticles comprises 385nmol of amino group. The silicon fluorescent nanoparticles Ru(bpy)3 / SiO2 have the advantages of uniform size, high monodispersity, mean diameter of 70+ / -6nm, high light stability and difficult dye leakage in aqueous solution. The fluorescent probe is applied to a protein microarray chip to detect HIV p24 antigen after marking streptavidin; the analysis method is a sandwich fluorescence immunoassay method; and the result shows that the fluorescence intensity is in good positive relationship with p24 concentration and the analytical sensitivity is 3.1ng / mL. The result shows that the nanoparticles, serving as a novel fluorescent probe, can be applied to the systems of the protein microarray chip and fluorescence immunoassay and the like for high flexibility detection.

The present invention is HIV virus antibody / antigen diagnosis kit and its preparation process and detection method. The kit includes pre-coated enzyme-linked board with coated HIV antibody and P24 monoclonal antibody, rabbit anti-P24 polyclonal antibody labeled with biotin, conjugate of horseradish peroxidase labeled avidin and HIV antigen, detergent solution of phosphate buffer containing Tween, developing solution A of citrate buffer containing hydrogen peroxide, developing solution B of citrate buffer containing tetramethyl benzidine, terminating solution containing sulfuric acid solution, sample diluting solution containing phosphate buffer, normal human serum as positive contrast, HIV antibody serum as positive contrast, and P24 antigen serum as positive contrast. The present invention can detect HIV antibody and P24 antigen simultaneously in raised specificity and sensitivity and is suitable for diagnosis of human immune deficiency virus antibody.

The invention provides a fourth-generation HIV (Human Immunodeficiency Virus) antibody antigen test paper, a preparation method and an application thereof. The test paper comprises a water-absorbing filter paper, a nitrocellulose membrane, a colloidal gold pad, a sample pad and a reaction supporting substance, wherein the sample pad, the colloidal gold pad, the nitrocellulose membrane and the water-absorbing filter paper are overlapped and spliced on the outer surface of the reaction supporting substance in turn. Thus, the fourth-generation HIV antibody antigen test paper provided by the invention has the advantages of convenience in use, simpleness in operation, convenience in popularization and capability of simultaneously identifying P24 antigen positive result and HIV antibody positive result on the same test paper.

The invention provides a diagnostic kit for jointly detecting an HIV antigen and an HIV antibody. The HIV-1type p24 antigen and the HIV-1 / 2 type antibody are qualitatively detected by adopting the immunoadsorption test principle of a double antibody sandwich method and a double antigen sandwich method and combining a time-resolved fluorescence immunoassay technique; the window period of existing HIV detection can be shortened to be 2-3 weeks, and the diagnostic kit is beneficial for early diagnosis of an HIV and also can serve as a basis for prognostically judging and evaluating the antiviral therapy effect; meanwhile, the kit further has the advantages of being high in specificity and sensitivity, good in repeatability, excellent in stability, wide in measurable range, high in detection automation degree, free of environmental pollution and the like.

The invention relates to an immune chromatography kit used for simultaneously realizing screening of three or four of four major infectious diseases (AIDS, hepatitis B, hepatitis C and syphilis) by a single experiment. The invention has the characteristics as follows: the particle diameter of a colloidal gold is increased to 80 to 90nm from the typical 20 to 40nm, so that the sensitivity of the colloidal gold is improved; two enveloping modes are available, for instance, all test items are underlined on the same NC membrane with one separate from another, and assembled on the same test strip finally, or, for instance, all test items are separated and underlined on different NC membranes, and are arranged and assembled separately; and then, the envelope antigens / antibodies of all test items are mixed together and underlined, thereby resulting in only one test line. The invention has the advantages that the invention can be applied to screening prior to physical examination, blood donation, blood transfusion, surgery and the like, so that the test time can be saved, the efficiency can be improved, the HIV P24 antigens can be tested as early as possible, and the window period of HIV test can be shortened.

The invention relates to a test paper strip for detecting a P24 antigen and particularly relates to a preparation method of a carbon quantum dot test paper strip for detecting a P24 antigen. The preparation method comprises the following steps of: bonding a sample pad and a water absorption pad respectively at two ends of a bottom plate, preparing a P24 carbon quantum dot pad and a P24 nitrocellulose membrane, bonding the sample pad, the P24 carbon quantum dot pad, the P24 nitrocellulose membrane and the water absorption pad in a lapping way in sequence on the bottom plate to obtain a test paper plate, cutting the test paper plate into a plurality of test paper strips conforming to defined widths, and hermetically storing the test paper strips. According to the invention, a known specific antibody or antigen is fixed in a zone of the cellulose membrane at first, a sample to be detected is added on the sample pad, a carbon quantum dot marking reagent on the carbon quantum dot pad is dissolved, and a large amount of carbon quantum dots are gathered on a detection band, so that bright light is emitted and specific immunologic diagnosis is achieved. The method is high in sensitivity and low in toxicity or free from toxicity in a detection process.

The invention discloses an acid treating agent for HIV detection, a sample pretreatment method, a kit and a detection method, and belongs to the technical field of in vitro diagnosis and detection. The acid treating agent is mainly formed by mixing an organic acid solution with concentration of 0.1-1.0mol / L and an inorganic acid solution with concentration of 0.01-0.1mol / L, or an organic acid solution which is with concentration of 0.1-1.2mol / L, wherein the pH value of the acid treating agent is 2.5-4.5. The acid treating agent can well separate out p24 antigen and p24 antibody in a sample. The invention also discloses the HIV detection kit adopting the acid treating agent, the sample pretreatment method and the detection method, and the HIV detection kit, the sample pretreatment method and the detection method have the advantage of high sensitivity.

The invention provides a novel purpose of triptolide and a triptolide derivative. The triptolide can obviously inhibit the GFP fluorescent protein and P24 antigen rise effect in a phorbol ester activated lymphocyte model. When the concentration of the lymphocyte concentration is higher, the GFP positive cell percentage and the P24 antigen concentration are lower; the negative dosage-effect relationship exists. Even when the concentration of the methylprednisolone is as high as 400 uM, the inhibition effect cannot reach the inhibition effect of the triptolide with the concentration being 0.02 uM; the cell apoptosis proportion obviously exceeds the triptolide with the concentration being 0.02 uM. According to the principle, the triptolide inhibits the G0 / G1 period cell proportion rise and S period cell proportion descending due to PMA; the cell period is promoted to be stopped in the unactivated state; the triptolide achieves the effect of inhibiting the lymphocyte cell proliferation and activation through regulating the cell period; meanwhile, the effect of inhibiting the virus replication is also achieved. The triptolide and the triptolide derivative can replace glucocorticoid analogues or can be combined with the glucocorticoid analogues to be used, and are used for treating and / or preventing lung injury diseases.

The invention discloses a monoclonal antibody hybridoma cell expressing an HIV P24 and an application, wherein, through separating HIV virus in an HIV positive infector, the P24 protein gene of the separated virus is enlarged; P24 protein can be obtained through external expression of carriers and purification; after using the purified P24 protein to immunize the mice, the spleen B cells of the immunized mice are separated out, and an hybridoma cell efficiently expressing a P24 monoclonal antibody (whiov-P24C-MoAb, CCTCC NO:C200818) can be obtained by adopting a hybridoma technology; and the P24 monoclonal antibody can be in specific binding with P24 protein of HIV virus for detecting the expression of P24 antigen. The P24 monoclonal antibody can be in specific binding with P24 protein ofHIV virus, interferences of other bad reactions can be reduced when being used for specific detection of P24 protein.

The invention provides immunogenic compositions which enhance the duration and strength of the immune response in a mammal. The immunogenic compositions contain an HIV antigen, an immunomer and an adjuvant. The HIV antigen can be a whole-killed HIV virus devoid of outer envelope protein gp120. Alternatively, the HIV antigen can be a whole-killed HIV virus, or a p24 antigen. Also provided are kits, the components of which, when combined, produce the immunogenic compositions of the invention. The invention also provides methods of making the immunogenic compositions, by combining an HIV antigen, an immunomer and optionally an adjuvant. The invention further provides a method of immunizing a mammal, by enhancing an immune response in the mammal by administering to the mammal an immunogenic composition containing an HIV antigen, an immunomer and optionally an adjuvant. Also provided is a method of inhibiting in a mammal by administering to the mammal an immunogenic composition containing an HIV antigen, an immunomer and optionally an adjuvant.

The invention discloses a liquid-chip HIV-antigen antibody combined detection kit and a detecting method and belongs to the field of immunoassay. The kit comprises microspheres respectively covered with HIV gp41, p17, p24, p31, p66 and gp120 antigens, a biotinylated anti-human secondary antibody, an SA-PE solution, microspheres covered with a p24 monoclonal antibody, and a monoclonal antibody labeled with fluorescein and matching the p24 monoclonal antibody. Combined detection for six HIV antibodies and a P24 antigen can be performed simultaneously through a small amount of a sample. Compared with an immunoblotting method, the kit and the detecting method are high in sensitivity and specificity. Through the kit and the detecting method, the HIV antibodies can be detected timely in the earlier period of infection, thus achieving early detection and early intervention of HIV infection, reducing HIV transmission and ensuring safety of blood transfusion. The kit and the detecting method have a wide application prospect.

The present invention to a monoclonal antibody for resisting human immune deficiency virus I type p24 protein and its application, belonging to the field of biological technology. The immunogen of monoclonal antibody is HIV-IB substype p24 gene engineering recombinant protein. Said monoclonal antibody can be combined with other monoclonal antibody or polyclonal antibody or can be used as label of radioactive isolope, enzyme, fluorescin compound, chemical luminescence comound or colloidal metal ion, can be used for preparing various qualitative or quantitative detection liquors and reagent of p24 antigen in cultured supernatant fluid or cell or tissue.

The invention discloses application of resveratrol and analogs of resveratrol in serving as HIV latent virus reservoir activating agents.The inventor proves that resveratrol can effectively stimulate rising of expression of GFP protein and a P24 antigen in a cell model through the HIV latent cell model J-lat full length clone 10.6.Thus, resveratrol and derivatives thereof can be independently used or jointly used with other activating medicine for activating the HIV latent virus reservoir in the body of an HIV patient and can serve as an alternative medicine molecule for curing aids.

The invention discloses a preparation method of an acquired immune deficiency syndrome antigen detection chip. The preparation method comprises the following steps: step one, synthesizing novel core-shell silicon dioxide fluorescence nanoparticles; step two, marking streptavidin; and step three, preparing a protein chip based on HIV p24 antigen detection. According to the preparation method, according to the antigen-antibody high specific immunity reaction, the detection signal and the detection sensitivity are improved by adopting rare earth fluorescence nanoparticles as markers, and a micro-array protein chip is prepared on the basis, so that few samples are needed, a great number of patients can be detected in a high throughout, high sensitivity and rapidness manner within an extremely short time, raw materials, manpower, material resources and time aregreatly saved.

The invention provides immunogenic compositions which enhance the duration and strength of the immune response in a mammal. The immunogenic compositions contain an HIV antigen, an immunomer and an adjuvant. The HIV antigen can be a whole-killed HIV virus devoid of outer envelope protein gp120. Alternatively, the HIV antigen can be a whole-killed HIV virus, or a p24 antigen. Also provided are kits, the components of which, when combined, produce the immunogenic compositions of the invention. The invention also provides methods of making the immunogenic compositions, by combining an HIV antigen, an immunomer and optionally an adjuvant. The invention further provides a method of immunizing a mammal, by enhancing an immune response in the mammal by administering to the mammal an immunogenic composition containing an HIV antigen, an immunomer and optionally an adjuvant. Also provided is a method of inhibiting in a mammal by administering to the mammal an immunogenic composition containing an HIV antigen, an immunomer and optionally an adjuvant.

The invention discloses a method and a device for detecting an HIV-1P24 antigen based on a silicon nitride (SiNx) solid nanopore, and the method comprises the following steps: S1, a pretreatment step: carrying out pretreatment on a SiNx film chip with a window before use; s2, preparing a nanopore, namely preparing the required nanopore in the SiNx thin film chip by using a multistage current pulse breakdown method; s3, detecting an ion blocking current pulse signal generated by the nanopore in the sample; and S4, analyzing, detecting and calculating the detection limit of the sample. According to the present invention, the HIV-1P24 antigen molecule can be well detected, the spatial structure change of the sample during the translocation can be inferred, and the HIV-1P24 antigen molecule at the low concentration can be detected. The method and the device have the advantages of rapidness, detection timeliness, high sensitivity, high signal-to-noise ratio and high flux, further shorten the window period of HIV detection, and strive for earlier diagnosis opportunities for infected persons.

The invention discloses a method for efficiently and quickly screening HIV P24 antigen nucleic acid aptamer. The method includes that subduction index enriched ligand system evolution (SELEX) technology and qPCR technology are utilized, streptavidin is adopted to prepare single-stranded DNA, TPBS is used to wash away nonspecific single-stranded DNA, comerical carboxylated agar magnetic beads are used as a separation medium for selex screening, and the HIV P24 antigen nucleic acid aptamer is obtained by screening from a random oligonucleotide library, so that screening efficiency is improved. Therefore, the method can serve as early detection technology, a method which is high in sensitivity, low in cost and simple and convenient to operate is provided for clinical detection, a new specific carrier is provided for tumor treatment, and a foundation is laid for screening other single target protein and tumor serum marker nucleic acid aptamer. The method is high in screening efficiency, short in period and low in cost.

The invention discloses a monoclonal antibody hybridoma cell expressing an HIV P24 and an application, wherein, through separating HIV virus in an HIV positive infector, the P24 protein gene of the separated virus is enlarged; P24 protein can be obtained through external expression of carriers and purification; after using the purified P24 protein to immunize the mice, the spleen B cells of the immunized mice are separated out, and an hybridoma cell efficiently expressing a P24 monoclonal antibody (whiov-P24C-MoAb, CCTCC NO:C200818) can be obtained by adopting a hybridoma technology; and the P24 monoclonal antibody can be in specific binding with P24 protein of HIV virus for detecting the expression of P24 antigen. The P24 monoclonal antibody can be in specific binding with P24 protein ofHIV virus, interferences of other bad reactions can be reduced when being used for specific detection of P24 protein.

The invention relates to a novel separated binding protein containing an HIV-1 P24 antigen binding domain, and researches on the aspects of preparation, application and the like of the binding protein. The binding protein comprises at least one complementarity determining region, is high in activity, has very high affinity with HIV-1 P24 protein, and can be widely applied to the field of detection of the HIV-1 P24 protein.

The invention relates to a test paper strip for detecting a P24 antigen and particularly relates to a preparation method of a carbon quantum dot test paper strip for detecting a P24 antigen. The preparation method comprises the following steps of: bonding a sample pad and a water absorption pad respectively at two ends of a bottom plate, preparing a P24 carbon quantum dot pad and a P24 nitrocellulose membrane, bonding the sample pad, the P24 carbon quantum dot pad, the P24 nitrocellulose membrane and the water absorption pad in a lapping way in sequence on the bottom plate to obtain a test paper plate, cutting the test paper plate into a plurality of test paper strips conforming to defined widths, and hermetically storing the test paper strips. According to the invention, a known specific antibody or antigen is fixed in a zone of the cellulose membrane at first, a sample to be detected is added on the sample pad, a carbon quantum dot marking reagent on the carbon quantum dot pad is dissolved, and a large amount of carbon quantum dots are gathered on a detection band, so that bright light is emitted and specific immunologic diagnosis is achieved. The method is high in sensitivity and low in toxicity or free from toxicity in a detection process.

The invention discloses an acid treatment agent for HIV detection, a sample pretreatment method, a kit and a detection method, and belongs to the technical field of in vitro diagnosis and detection. The acid treatment agent is mainly composed of an organic acid solution with a concentration of 0.1-1.0mol / L and an inorganic acid solution with a concentration of 0.01-0.1mol / L, or an organic acid solution with a concentration of 0.1-1.2mol / L. The pH value of the acid treatment agent is 2.5-4.5. Using the above-mentioned acidic treatment agent, the p24 antigen and p24 antibody in the sample can be well separated. The HIV detection kit, the sample pretreatment method and the detection method using the above acidic treatment agent have the advantage of high sensitivity.

The invention discloses a sensor detection kit based on a 96-well plate immobilized molecular motor and a method for P24 antigen in vitro detection.The kit is composed of a molecular motor sensor detection plate, and the detection plate is formed by immobilizing an F0F1-ATP enzyme molecular motor on a 96-well ELISA plate; meanwhile, a detection probe (P24 antibody) is combined to form a molecular motor biosensor for capturing a target. The detection method mainly comprises the following steps: (1) placing a sample in the detection plate, and capturing a target object by the sensor; (2) adding an ATP (adenosine triphosphate) synthesis solution containing ADP (adenosine triphosphate), and reacting And (3) adding an ATP detection reagent, quickly and uniformly mixing, and starting a chemical light emission detector to measure the luminous intensity. According to the present invention, the stability and the uniformity of the 96-well plate immobilized molecular motor, the mutual conversion characteristic of the kinetic energy and the chemical energy of the molecular motor, and the high sensitivity and the rapid performance of the chemiluminescence are utilized to detect the antigen, and the porosity of the 96-well plate enables the rapid and stable detection to be achieved while the high throughput screening requirement can be met.

The present invention relates to a pharmaceutical composition and health functional food having anti-HIV-1 inhibitory activity containing phloroglucinol derivative, 6,6′-bieckol as an effective ingredient, EC extract and its phloroglucinol derivative, 6,6′-bieckol according to the present invention does not show cytotoxic effect compared to other tannin, and have effects to inhibit the HIV-1 induced syncytia formation and the p24 antigen production as well as the HIV-1 reverse transcriptase activity.